- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00770952
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.
Effects of Pioglitazone in Combination With Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients With Type 2 Diabetes Mellitus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Tight glycemic control is mandatory for the prevention and treatment of vascular complications in patients suffering from diabetes mellitus. After onset of Type 2 Diabetes, patients are usually treated with diet along with or without different combinations of oral drugs. One first-line drug class are sulfonylurea drugs that are preferably provided to patients who are not obese. The mode of action of sulfonylurea drugs is to increase beta-cell secretion, but it could be shown that they lead to deterioration of the beta-cell secretion product over time, resulting in increased proinsulin secretion. Since proinsulin is an independent cardiovascular risk factor, recent publications have demonstrated an increased risk for cardiovascular events in patients treated with sulfonylurea drugs as compared to other treatment methods.
Combination therapy of sulfonylurea drugs with glitazones has been shown to counterbalance the effect of deteriorated beta-cell secretion and to improve insulin sensitivity and the levels of proinsulin, C-peptide and other laboratory surrogate markers for cardiovascular risk. Proving that the treatment of diabetic patients with higher doses of beta cytotropic agents can be avoided and beta-cell function can be preserved by using pioglitazone in combination with low dose sulfonylurea drugs, it will be possible to optimize the treatment of patients with type 2 diabetes who are not controlled efficiently by sulfonylurea drugs monotherapy.
In this study patients will be enrolled who are inefficiently treated with a Glimepiride monotherapy. Patients will be either randomized to a combinational therapy of Pioglitazone and Glimepiride or Glimepiride monotherapy. If possible, study medication will be up-titrated to maximal dosage levels in both treatment arms to observe maximal and comparable treatment effects. Stable effects on beta-cell function will be observed after 24 weeks of treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
-
-
Baden-Württemberg
-
Villingen-Schwenningen, Baden-Württemberg, Germany
-
-
Bayern
-
Aschaffenburg, Bayern, Germany
-
Ingolstadt, Bayern, Germany
-
-
Hessen
-
Frankfurt, Hessen, Germany
-
Frielendorf, Hessen, Germany
-
Rotenburg, Hessen, Germany
-
-
Niedersachsen
-
Hannover, Niedersachsen, Germany
-
-
Nordrhein-Westfalen
-
Dortmund, Nordrhein-Westfalen, Germany
-
Siegen, Nordrhein-Westfalen, Germany
-
-
Rheinland-Pfalz
-
Kallstadt, Rheinland-Pfalz, Germany
-
Mainz, Rheinland-Pfalz, Germany
-
Mayen, Rheinland-Pfalz, Germany
-
Neuwied, Rheinland-Pfalz, Germany
-
Rhaunen, Rheinland-Pfalz, Germany
-
-
Saarland
-
Friedrichsthal, Saarland, Germany
-
-
Sachsen
-
Meißen, Sachsen, Germany
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 Diabetes according to the American Diabetes Association Criteria.
- Treatment with Glimepiride monotherapy (1-3 mg per day) 3 months before entering the study.
- Glycosylated hemoglobin greater than 6.5%, but less than 8.5% and/ or fasting plasma glucose greater than 7 mmol/l within the last 4 weeks.
- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
Exclusion Criteria:
- Type 1 Diabetes mellitus.
- History of hypersensitivity to the study drugs or to drugs with similar chemical structures.
- Progressive fatal disease.
- History of drug or alcohol abuse during the last 5 years.
- More than one unexplained episode of severe hypoglycemia within 6 months prior to entering the study.
- A history of significant cardiovascular (New York Heart Association stage I - IV), respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.8 mg/dl; glomerular filtration rate less than 40 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease, history of macular edema.
- Blood donation within the last 30 days.
Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- CYP2C9 inductors
- CYP2C9 inhibitors
- rifampicin
- fluconazole
- drugs used for treating type 2 diabetes (insulin, insulin analogous compounds and oral antidiabetic drugs)
- Pretreatment with thiazolidinediones within the last 12 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pioglitazone 30 mg to 45 mg QD + Glimepiride 2 mg to 4 mg QD
|
Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to: Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to: Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks.
Other Names:
|
Active Comparator: Glimepiride 4 mg to 6 mg QD
|
Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to: Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to: Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in Homeostatic Model Assessment - Beta cell.
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in Glycosylated Hemoglobin.
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in oral glucose tolerance testing.
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in Insulin.
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in Proinsulin.
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in C-peptide.
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in High sensitivity C-Reactive Protein.
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in Adiponectin.
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in Homeostatic Model Assessment - Sensitivity.
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in Triglycerides
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in Low Density Lipoprotein-Cholesterol
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in High Density Lipoprotein-Cholesterol
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Change from Baseline in Total Cholesterol
Time Frame: Week: 24 or Final Visit beyond week 12.
|
Week: 24 or Final Visit beyond week 12.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATS K020
- 2006-002271-41 (EudraCT Number)
- D-PIO-112 (Other Identifier: Takeda ID)
- U1111-1114-3221 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Pioglitazone and Glimepiride
-
IKFE Institute for Clinical Research and DevelopmentCompletedType 2 Diabetes Mellitus | Insulin ResistanceGermany
-
Kurume UniversityUnknownTo Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT ImagingJapan
-
TakedaCompleted
-
TakedaCompletedDiabetes Mellitus | DyslipidemiasGermany
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States, Germany, Peru, Spain, United Kingdom, India, Philippines, Russian Federation, Hong Kong
-
Merck Sharp & Dohme LLCCompleted
-
Pusan National University HospitalUnknownType 2 Diabetes MellitusKorea, Republic of
-
TakedaCompletedDiabetes MellitusUnited States
-
TakedaCompletedDiabetes MellitusUnited States, Argentina, Canada, Chile